AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 132 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $794,000 | +763.0% | 52,477 | +330.1% | 0.00% | – |
| Q2 2022 | $92,000 | -53.1% | 12,200 | -43.4% | 0.00% | – |
| Q1 2022 | $196,000 | -79.2% | 21,537 | -84.0% | 0.00% | – |
| Q4 2021 | $944,000 | +108.8% | 134,400 | +239.5% | 0.00% | – |
| Q3 2021 | $452,000 | +108.3% | 39,583 | +225.5% | 0.00% | – |
| Q1 2021 | $217,000 | -83.3% | 12,162 | -87.3% | 0.00% | – |
| Q4 2020 | $1,296,000 | +39.7% | 95,882 | +21.7% | 0.00% | – |
| Q3 2020 | $928,000 | -7.6% | 78,800 | +15.7% | 0.00% | – |
| Q2 2020 | $1,004,000 | -66.5% | 68,086 | -69.3% | 0.00% | -100.0% |
| Q1 2020 | $2,994,000 | -28.5% | 221,727 | +27.9% | 0.00% | 0.0% |
| Q4 2019 | $4,189,000 | -14.2% | 173,300 | -31.8% | 0.00% | 0.0% |
| Q3 2019 | $4,883,000 | -76.0% | 254,115 | -63.0% | 0.00% | -66.7% |
| Q2 2019 | $20,308,000 | +201.9% | 687,220 | +385.3% | 0.00% | 0.0% |
| Q1 2019 | $6,727,000 | -22.9% | 141,600 | -41.4% | 0.00% | 0.0% |
| Q4 2018 | $8,726,000 | -40.7% | 241,710 | +1.2% | 0.00% | -40.0% |
| Q3 2018 | $14,707,000 | -3.2% | 238,945 | +6.2% | 0.01% | 0.0% |
| Q2 2018 | $15,199,000 | +5.4% | 224,995 | -15.4% | 0.01% | 0.0% |
| Q1 2018 | $14,425,000 | -47.1% | 265,900 | -41.7% | 0.01% | -50.0% |
| Q4 2017 | $27,243,000 | -9.0% | 455,957 | -26.0% | 0.01% | -9.1% |
| Q3 2017 | $29,953,000 | +142.0% | 616,300 | +161.7% | 0.01% | +120.0% |
| Q2 2017 | $12,375,000 | +18.2% | 235,479 | +2.0% | 0.01% | 0.0% |
| Q1 2017 | $10,466,000 | +27.8% | 230,775 | +6.6% | 0.01% | 0.0% |
| Q4 2016 | $8,190,000 | -56.6% | 216,404 | -56.7% | 0.01% | -44.4% |
| Q3 2016 | $18,876,000 | +460.8% | 500,185 | +161.5% | 0.01% | +350.0% |
| Q2 2016 | $3,366,000 | +297.9% | 191,300 | +174.8% | 0.00% | – |
| Q1 2016 | $846,000 | -75.4% | 69,615 | -50.7% | 0.00% | -100.0% |
| Q4 2015 | $3,438,000 | -66.8% | 141,200 | -75.8% | 0.00% | -75.0% |
| Q3 2015 | $10,345,000 | +60.1% | 583,208 | +59.3% | 0.00% | +33.3% |
| Q2 2015 | $6,463,000 | +173.3% | 366,200 | +385.4% | 0.00% | – |
| Q1 2015 | $2,365,000 | – | 75,445 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |